Ken Griffin Inovio Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$0.35 - $0.53 $14,489 - $21,942	41,400 Added 12.45%	373,800 $190,000
Q3 2023 Nov 14, 2023	SELL	$0.38 - $0.58 $11,704 - $17,864	-30,800 Reduced 8.48%	332,400 $129,000
Q2 2023 Aug 14, 2023	SELL	$0.39 - $0.94 $5,460 - $13,160	-14,000 Reduced 3.71%	363,200 $163,000
Q1 2023 May 15, 2023	SELL	$0.79 - $1.91 $114,550 - $276,950	-145,000 Reduced 27.77%	377,200 $309,000
Q4 2022 Feb 14, 2023	SELL	$1.41 - $2.5 $199,374 - $353,500	-141,400 Reduced 21.31%	522,200 $814,000
Q3 2022 Nov 14, 2022	BUY	$1.66 - $2.79 $178,782 - $300,483	107,700 Added 19.37%	663,600 $1.15 Million

281K

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $459M
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.